The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis

Journal of Cancer Survivorship

Volumn 4, Issue 2, 2010, Pages 128-139

  Haseen, Farhana ^a   Murray, Liam J ^a   Cardwell, Chris R ^a   O'Sullivan, Joe M ^a   Cantwell, Marie M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

ADT; Body composition; Prostate cancer; Systematic review

Indexed keywords

ANTIANDROGEN;

BODY COMPOSITION; BODY MASS; HUMAN; LONGITUDINAL STUDY; MALE; META ANALYSIS; PATHOLOGY; PROSTATE TUMOR; PSYCHOLOGICAL ASPECT; REVIEW; SURVIVAL RATE; SURVIVOR; TREATMENT OUTCOME; PROSTATIC NEOPLASMS; PSYCHOLOGY;

ANDROGEN ANTAGONISTS; BODY COMPOSITION; BODY MASS INDEX; HUMANS; LONGITUDINAL STUDIES; MALE; PROSTATIC NEOPLASMS; SURVIVAL RATE; SURVIVORS; TREATMENT OUTCOME;

EID: 77953539676     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-009-0114-1     Document Type: Review

References (59)

1. Demers RY, Tiwari A, Wei J, Weiss LK, Severson RK, Montie J. Trends in the utilization of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality. Cancer. 2001; 92: 2309-17.
2. Hussain S, Gunnell D, Donovan J, McPhail S, Hamdy F, Neal D, et al. Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. BJU Int. 2008; 101: 547-55.
3. Gotkas S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol. 1999; 26: 162-73.
4. Morley JE. Testosterone and behavior. Clin Geriatr Med. 2003; 19: 605-16.
5. Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. J Endocrinol Investig. 1999; 22: 110-6.
6. Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol. 2000; 163: 1743-6.
7. Stone P, Hardy J, Huddart R, A'Hern R, Richards M. fatigue in patients with prostate cancer receiving therapy. Eur J Cancer. 2000; 36: 1134-41.
8. Burton BT, Foster WR, Hirsch J, van Itallie TB. Health implications of obesity: an NIH Consensus Development Conference. Int J Obes. 1985; 9: 155-70.
9. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360: 103-6.
10. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997; 337: 295-300.
11. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2003; 61: 1285-90.
12. Messing E, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886. April 29, 2003; AUA Annual Meeting, Chicago, [Abstract #1480].
13. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005; 352: 154-64.
14. Potter J, Langhorne P, Roberts M. Routine protein energy supplementation in adults: systematic review. BMJ. 1998; 317: 495-501.
15. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range and the size of a sample. BMC Med Res Methodol. 2005; 5: 13.
16. Smith MR, Lee H, McGovem F, Fallon MA, Goode M, Zietman AL, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008; 112: 2188-94.
17. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004; 22: 2546-53.
18. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002; 167: 2361-7.
19. Boxer RS, Kenny AM, Dowsett R, Taxel P. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. Aging Male. 2005; 8: 207-12.
20. Denti L, Pasolini G, Cortellini P, Ferretti S, Sanfelici L, Ablondi F, et al. Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a). Clin Chem. 1996; 42: 1176-81.
21. Galvao DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008; 102: 44-7.
22. Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer. 2005; 104: 1633-7.
23. Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab. 2005; 90: 657-60.
24. Nowicki M, Bryc W, Kokot F. Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade. J Endocrinol Investig. 2001; 24: 31-6.
25. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001; 86: 4261-7.
26. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004; 63: 742-5.
27. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Anne Fallon M, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002; 87: 599-603.
28. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006; 91: 1305-8.
29. Tayek JA, Heber D, Byerley LO, Steiner B, Rajfer J, Swerdloff RS. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism. 1990; 39: 1314-9.
30. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol. 2004; 171: 2272-6.
31. Selly S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess. 1997; 1(2): 31-5.
32. Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer. 2002; 95: 2136-44.
33. Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001; 86: 2787-91.
34. van Londen GJ, Levy ME, Perera S, Nelson JB, Greenspan SL. Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study. Crit Rev Oncol Hematol. 2008; 68: 172-7.
35. Basaria S, Leib J, Tang AM, DeWeese T, Carducci M, Eisenberger M, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf). 2002; 56: 779-86.
36. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999; 84: 2647-53.
37. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with nodepositive prostate cancer. N Engl J Med. 1999; 341: 1781-8.
38. Gong EM, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1977-83.
39. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer. 2007; 109: 1192-202.
40. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, et al. Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer. 2007; 110: 2691-9.
41. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24: 4448-56.
42. Arrer E, Jungwirth A, Mack D, Frick J, Patsch W. Treatment of prostate cancer with gonadotropin-releasing hormone analogue: effect on lipoprotein[a]. J Clin Endocrinol Metab. 1996; 81: 2508-11.
43. Bassey EJ, Fiatarone MA, O'Neill EF, Kelly M, Evans WJ, Lipsitz LA. Leg extensor power and functional performance in very old men and women. Clin Sci (Lond). 1992; 82: 321-7.
44. Evans WJ. What is sarcopenia? J Gerontol A Bio Sci Med Sci. 1995; 50: 5-8.
45. Taaffe DR. Sarcopenia. Exercise as a treatment strategy. Aus Farm Physician. 2006; 35: 130-4.
46. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA, Evans WJ. High-intensity strength training in nonagenarians. Effects on skeletal muscle. JAMA. 1990; 263: 3029-34.
47. Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006; 38: 2045-52.
48. Culos-Reed SN, Robinson JL, Lau H, O'Connor K, Keats MR. Benefits of a physical activity intervention for men with prostate cancer. J Sport Exerc Psychol. 2007; 29: 118-27.
49. Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003; 21: 1653-9.
50. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol. 2002; 168: 429-35.
51. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, van Poppel H, Tammela TL, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6. 3 years of follow-up. J Urology. 2000; 164: 1579-82.
52. Verhelst J, Denis L, van Vliet P, van Poppel H, Braeckman J, van Cangh P, et al. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf). 1994; 41: 525-30.
53. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. American Society of Clinical Oncology recommendations for the initial hormonalmanagementof androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004; 22: 2927-41.
54. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology. 1998; 51: 389-96.
55. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, et al. A randomised comparison of Casodex (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998; 33: 447-56.
56. Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol. 1999; 17: 2027-38.
57. Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, et al. Bicalutamide (Casodex) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol. 2005; 76: 4-10.
58. Pietrobelli A, Heymsfield SB, Wang ZM, Gallagher D. Multi-component body composition models: recent advances and future directions. Eur J Clin Nutr. 2001; 55: 69-75.
59. Higgins JPT, Green S, editor. Cochrane handbook for systematic reviews of interventions. Version 5. 0. 2, Section 16. 1. 3. 2, September 2009. Available from: http://www. cochrane-handbook. org/.